RT Journal Article
SR Electronic
T1 Overexpression of transposable elements underlies immune overdrive and poor clinical outcome in cancer patients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.14.20129031
DO 10.1101/2020.07.14.20129031
A1 Zhu, Xiaoqiang
A1 Fang, Hu
A1 Gladysz, Kornelia
A1 Barbour, Jayne A.
A1 Wong, Jason W. H.
YR 2020
UL http://medrxiv.org/content/early/2020/07/17/2020.07.14.20129031.abstract
AB Increased immune infiltration in tumor tissue is usually associated with improved clinical outcome, but excessive infiltration can lead to worst prognosis. The factors underlying such immune overdrive phenotype remains unknown. Here, we investigate the contribution of transposable element (TE) expression to immune response and clinical outcome in cancer. Using colorectal cancer as a model, we develop a TE expression score, showing that highest scores are predicative of immune overdrive and poor outcome independent of microsatellite instability and tumor mutation burden. TE expression scores from cell lines treated with DNA methyltransferase inhibitors show that TEs are directly responsible for driving excess immune infiltration. A pan-cancer survey of TE expression further identify a subset of kidney cancer patients with similar immune overdrive phenotype and adverse prognosis. Together, our findings reveal that in cancer, TE expression underlies the immune overdrive phenotype and is an independent predictor of immune infiltration and prognosis.One Sentence Summary Transposable element expression is an independent predictor of immune infiltration and poor clinical outcome in cancer patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by Cancer Genomics Cloud pilot funds provided by Seven Bridges Genomics (XZ) and seed funding from The University of Hong Kong (JWHW).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The University of Hong Kong/Hospital Authority Hong Kong West Cluster. UW 18-599All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesTCGA CRC RNA sequencing data were directly analysed on Cancer Genomics Cloud using a custom pipeline [http://www.cancergenomicscloud.org/]. The processed TE expression for pan-cancer was downloaded from [http://research-pub.gene.com/REdiscoverTEpaper/]. CRC Copy Number GISTIC2 level 4 data was downloaded from Broad GDAC Firehose [http://gdac.broadinstitute.org/runs/analyses_2016_01_28/data/COADREAD/20160128/]. The clinical data, gene program pathways were obtained from [https://xenabrowser.net/]. The TCR/BCR index scores and genetic changes were downloaded from the Supplementary table of the pan-cancer immune landscape paper (PMID: 29628290). Three cell line datasets were downloaded from [https://www.ncbi.nlm.nih.gov/geo/] under the accession number of (i) GSE5816, (ii) GSE80137, and (iii) GSE22250.